TY - JOUR
T1 - Deoxycholic Acid and Risks of Cardiovascular Events, ESKD, and Mortality in CKD
T2 - The CRIC Study
AU - Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
AU - Frazier, Rebecca
AU - Cai, Xuan
AU - Lee, Jungwha
AU - Bundy, Joshua D.
AU - Jovanovich, Anna
AU - Chen, Jing
AU - Deo, Rajat
AU - Lash, James P.
AU - Anderson, Amanda Hyre
AU - Go, Alan S.
AU - Feldman, Harold I.
AU - Shafi, Tariq
AU - Rhee, Eugene P.
AU - Miyazaki, Makoto
AU - Chonchol, Michel
AU - Isakova, Tamara
N1 - Publisher Copyright:
© 2021
PY - 2022/1
Y1 - 2022/1
N2 - Rationale & Objective: Elevated levels of deoxycholic acid (DCA) are associated with adverse outcomes and may contribute to vascular calcification in patients with chronic kidney disease (CKD). We tested the hypothesis that elevated levels of DCA were associated with increased risks of cardiovascular disease, CKD progression, and death in patients with CKD. Study Design: Prospective observational cohort study. Setting & Participants: We included 3,147 Chronic Renal Insufficiency Cohort study participants who had fasting DCA levels. The average age was 59 ± 11 years, 45.3% were women, 40.6% were African American, and the mean estimated glomerular filtration rate was 42.5 ± 16.0 mL/min/1.73 m2. Predictor: Fasting DCA levels in Chronic Renal Insufficiency Cohort study participants. Outcomes: Risks of atherosclerotic and heart failure events, end-stage kidney disease (ESKD), and all-cause mortality. Analytical Approach: We used Tobit regression to identify predictors of DCA levels. We used Cox regression to examine the association between fasting DCA levels and clinical outcomes. Results: The strongest predictors of elevated DCA levels in adjusted models were increased age and nonuse of statins. The associations between log-transformed DCA levels and clinical outcomes were nonlinear. After adjustment, DCA levels above the median were independently associated with higher risks of ESKD (HR, 2.67; 95% CI, 1.51-4.74) and all-cause mortality (HR, 2.13; 95% CI, 1.25-3.64). DCA levels above the median were not associated with atherosclerotic and heart failure events, and DCA levels below the median were not associated with clinical outcomes. Limitations: We were unable to measure DCA longitudinally or in urinary or fecal samples, and we were unable to measure other bile acids. We also could not measure many factors that affect DCA levels. Conclusions: In 3,147 participants with CKD stages 2-4, DCA levels above the median were independently associated with ESKD and all-cause mortality.
AB - Rationale & Objective: Elevated levels of deoxycholic acid (DCA) are associated with adverse outcomes and may contribute to vascular calcification in patients with chronic kidney disease (CKD). We tested the hypothesis that elevated levels of DCA were associated with increased risks of cardiovascular disease, CKD progression, and death in patients with CKD. Study Design: Prospective observational cohort study. Setting & Participants: We included 3,147 Chronic Renal Insufficiency Cohort study participants who had fasting DCA levels. The average age was 59 ± 11 years, 45.3% were women, 40.6% were African American, and the mean estimated glomerular filtration rate was 42.5 ± 16.0 mL/min/1.73 m2. Predictor: Fasting DCA levels in Chronic Renal Insufficiency Cohort study participants. Outcomes: Risks of atherosclerotic and heart failure events, end-stage kidney disease (ESKD), and all-cause mortality. Analytical Approach: We used Tobit regression to identify predictors of DCA levels. We used Cox regression to examine the association between fasting DCA levels and clinical outcomes. Results: The strongest predictors of elevated DCA levels in adjusted models were increased age and nonuse of statins. The associations between log-transformed DCA levels and clinical outcomes were nonlinear. After adjustment, DCA levels above the median were independently associated with higher risks of ESKD (HR, 2.67; 95% CI, 1.51-4.74) and all-cause mortality (HR, 2.13; 95% CI, 1.25-3.64). DCA levels above the median were not associated with atherosclerotic and heart failure events, and DCA levels below the median were not associated with clinical outcomes. Limitations: We were unable to measure DCA longitudinally or in urinary or fecal samples, and we were unable to measure other bile acids. We also could not measure many factors that affect DCA levels. Conclusions: In 3,147 participants with CKD stages 2-4, DCA levels above the median were independently associated with ESKD and all-cause mortality.
KW - Cardiovascular disease
KW - chronic kidney disease
KW - deoxycholic acid
KW - end-stage kidney disease
KW - mortality
UR - http://www.scopus.com/inward/record.url?scp=85122705375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122705375&partnerID=8YFLogxK
U2 - 10.1016/j.xkme.2021.09.004
DO - 10.1016/j.xkme.2021.09.004
M3 - Article
AN - SCOPUS:85122705375
SN - 2590-0595
VL - 4
JO - Kidney Medicine
JF - Kidney Medicine
IS - 1
M1 - 100387
ER -